News | May 18, 2021
Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
